Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oxurion NV Major Shareholding Notification 2023

Dec 1, 2023

3987_mrq_2023-12-01_f793636b-a958-4190-b238-b1fa93748c64.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

December 1, 2023

Regulated Information

Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:

Oxurion received a first transparency notification on November 22, 2023, from Atlas Special Opportunities, LLC indicating that as of November 13, 2023, it held 0 shares of the then outstanding 3,112,043,514 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1.

Oxurion received a second transparency notification on November 29, 2023, from Atlas Special Opportunities, LLC indicating that as of November 17, 2023, it held 241,545,893 shares of the then outstanding 3,489,458,972 shares, and therefore crossed above the threshold (5%) by virtue of the acquisition and sale of voting securities. See Annex 2.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV
Tom Graney
Chief Executive Officer
Tel: +32 16 75 13 10
[email protected]
US
Conway Communications
Mary T. Conway
[email protected]
Michael Dillen
Chief Business Officer
Tel: +32 16 75 13 10
[email protected]
  1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

________

FSMA FINANCIAL SERVICES AND
MARKETS AUTHORITY
Transparency notification
Form TR-1 BE
PARTI
1) Status of the notification
Final
2) Issuer
Identification number Name OXURION
0881-620-924
3) Reason for the notification
Acquisition or disposal of voting securities or voting rights
Downward crossing of the lowest threshold
4) Notification by
A person that notifies alone ÷.
5) Persons subject to the notification requirement
Name Address (for legal entities)
Atlas Special Opportunities LLC 2500 Westchester Avenue, Suite 401, Purchase, NY 10577
6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
Name Address (for legal entities)
Please continue entering the information in part II concerning the
persons referred to in Sections 5 and 6
Part II
7) Date on which the threshold is crossed
13/11/2023 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
u If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

10) Notified details

A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the
securities
Linked to securities Not linked to the
securities
Atlas Special Opportunities LLC 232.919.254 $\circ$ 0.00%
TOTAL ٥ 0.00% 0.00%

$0.00\%$ $\mathbf 0$ $0.00\%$

$\pm$

TOTAL D 0 0 0.00%

Start with "groups" of holders. Add subtotals with $\Sigma$ , and then finish with the persons who are "alone".

The totals, subtotals and % will be updated once you have clicked on .

Sign Envelope ID: F1BD79BA-C3D9-4995-8CCF-60F38B4394FF

B) Equivalent financial instruments After the transaction
Holders of equivalent
financial instruments
Type of financial instrument Expiration date Exercise period or
date
# of voting rights
that may be
acquired if the
Instrument is
exercised
% of voting rights Settlement
TOTAL $\bullet$ 0.00%

The totals will be updated once you have clicked on

TOTAL (A & B) # of voting rights % of voting rights
CALCULATE 0.00%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

JAN 1965
Holder Il cease to hold /
W.
will hold again
$-90$
жÆ
voting big

13) Additional information

On 9 November 2023, Atlas Special Opportunities LLC held 157,227,832 shares in Oxurion NV (= 5.05%, with denominator = 3,112,043,514). On 10 November 2023, Atlas Special Opportunities LLC sold
65,678,385 shares in Oxurion NV, as a result of which its shareholding decreased to 91,549,447 shares (= 2.94%, with denominator = 3,112,043,514). On 13 November 2023, Atlas Special Opportunities LLC sold
91,549,447 shares in Oxurion NV, as a result of which its shareholding decreased to 0 shares (= 0.00%, with denominator = 3,112,043,514).
Done at New York
On 17/11/2023 (DD/MM/YYYY)
Name & capacity Patrick Vance, proxyholder DocuSigned by:
Patrick Vance
Signature
55348237829544C

ANNEX 2

FSMA
FINANCIAL SERVICES AND
MARKETS AUTHORITY
Transparency notification
Form TR-1 BE
PARTI
1) Status of the notification
Final
2) Issuer
Name OXURION
Identification number 0881-620-924
3) Reason for the notification
Acquisition or disposal of voting securities or voting rights
4) Notification by
A person that notifies alone ÷.
5) Persons subject to the notification requirement
Name Address (for legal entities)
6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
Name Address (for legal entities)
Atlas Special Opportunities LLC 2500 Westchester Avenue, Suite 401, Purchase, NY 10577
persons referred to in Sections 5 and 6 Please continue entering the information in part II concerning the
Part II
7) Date on which the threshold is crossed
17/11/2023 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

3,489,458,972 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the
securities
Linked to securities Not linked to the
securities
Atlas Special Opportunities LLC 241,545,893 6.92%
TOTAL 241,545,893 6.92% 0.00%

$\pm$

Start with "groups" of holders. Add subtotals with $\Sigma$ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will b

gn Envelope ID: 7F03E731-92D9-4BC6-8FCE-52174CF89325

B) Equivalent financial instruments After the transaction
Holders of equivalent
financial instruments
Type of financial instrument Expiration date Exercise period or
date
# of voting rights
that may be
acquired if the
instrument is
exercised
% of voting rights Settlement
$+1$
TOTAL $\bf{0}$ 0.00%

The totals will be updated once you have clicked on

TOTAL (A & B) # of voting rights % of voting rights
CALCULATE 241,545,893 6.92%

12) In case of proxy voting for only one GM

,,,,,,,
Holder will cease to hold /
will hold again
voting rights as of

13) Additional information

On 15 November 2023, Atlas Special Opportunities LLC purchased 135,869,565 shares in Oxurion NV, as a result of which its shareholding increased to 135,869,565 shares (= 4,18%, with denominator =
3,247,913,079). On 17 November 2023, Atlas Special Opportunities LLC purchased 241,545,893 shares in Oxurion NV, as a result of which its shareholding increased to 377,415,458 shares (= 10.82%, with
denominator = 3,489,458,972). On the same day, Atlas Special Opportunities LLC sold 135,869,565 shares in Oxurion NV, as a result of which its shareholding decreased to 241,545,893 shares (= 6.92%, with
denominator = 3.489.458.972).
Done at New York
On 24/11/2023 (DD/MM/YYYY)
Name & capacity Patrick Vance, proxyholder

Attachments

  • $\frac{\epsilon}{N}$